Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management.

Abstract

Cytomegalovirus (CMV) infection is the most common viral infection in liver transplant recipients, affecting post-transplant patients and graft survival. Recent advances in diagnosis and management of CMV have led to marked reduction in incidence, severity, and its associated morbidity and mortality. CMV DNA assay is the most commonly used laboratory parameter to diagnose and monitor CMV infection. Current evidence suggests that both pre-emptive and universal prophylaxis approaches are equally justified in liver transplant recipients. Intravenous ganciclovir and oral valganciclovir are the most commonly used drugs for treatment of CMV disease. Most of the centre use valganciclovir prophylaxis for prevention of CMV disease in liver trasplant recipient. The aim of this article is to review the current standard of care for diagnosis and management of CMV disease in liver transplant recipients.

• Authors: Sanjay K Yadav, Sanjiv Saigal, Narendra S Choudhary, Sujit Saha, Navin Kumar, Arvinder S Soin
• Journal: Journal of clinical and experimental hepatology (J Clin Exp Hepatol) Vol. 7 Issue 2 Pg. 144-151 (Jun 2017) ISSN: 0973-6883 [Print] India
• PMID: 28663679 (Publication Type: Journal Article, Review)